These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 30187699

  • 1. Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience.
    Chung YS, Lee JY, Kim HS, Nam EJ, Kim SW, Kim YT.
    Yonsei Med J; 2018 Oct; 59(8):930-936. PubMed ID: 30187699
    [Abstract] [Full Text] [Related]

  • 2. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
    Chung YS, Park SY, Lee JY, Park JY, Lee JW, Kim HS, Suh DS, Kim YH, Lee JM, Kim M, Choi MC, Shim SH, Lee KH, Song T, Hong JH, Lee WM, Lee B, Lee IH.
    BMC Cancer; 2019 Apr 11; 19(1):341. PubMed ID: 30971221
    [Abstract] [Full Text] [Related]

  • 3. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY, Chung YS, Na K, Kim HM, Park CK, Nam EJ, Kim S, Kim SW, Kim YT, Kim HS.
    J Gynecol Oncol; 2017 Nov 11; 28(6):e73. PubMed ID: 28758379
    [Abstract] [Full Text] [Related]

  • 4. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I, Meydanli MM, Turan AT, Taskin S, Sari ME, Gungor T, Akbayir O, Ayhan A.
    Int J Clin Oncol; 2018 Apr 11; 23(2):329-337. PubMed ID: 29143144
    [Abstract] [Full Text] [Related]

  • 5. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Ren B, Guo W, Chen X.
    J Ovarian Res; 2016 Dec 02; 9(1):85. PubMed ID: 27912779
    [Abstract] [Full Text] [Related]

  • 6. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H, Maurer KA, Nutter B, Rose PG.
    Int J Gynecol Cancer; 2015 Jun 02; 25(5):823-9. PubMed ID: 25828750
    [Abstract] [Full Text] [Related]

  • 7. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X, Deng F, Lv M, Chen X.
    Arch Gynecol Obstet; 2017 Feb 02; 295(2):451-458. PubMed ID: 27913927
    [Abstract] [Full Text] [Related]

  • 8. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
    Zhang J, Liu N, Zhang A, Bao X.
    J Obstet Gynaecol Res; 2018 Sep 02; 44(9):1808-1816. PubMed ID: 30019801
    [Abstract] [Full Text] [Related]

  • 9. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A, Bodnar L, Wcisło GB, Jerzak MM, Szczylik C, Baranowski W.
    Ginekol Pol; 2008 Feb 02; 79(2):108-14. PubMed ID: 18510089
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
    Wilkinson-Ryan I, Frolova AI, Liu J, Stewart Massad L, Thaker PH, Powell MA, Mutch DG, Hagemann AR.
    Int J Gynecol Cancer; 2015 Jan 02; 25(1):63-8. PubMed ID: 25365590
    [Abstract] [Full Text] [Related]

  • 11. Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.
    Ayhan A, Ozkan NT, Sarı ME, Celik H, Dede M, Akbayır Ö, Güngördük K, Şahin H, Haberal A, Güngör T, Arvas M, Meydanlı MM.
    J Gynecol Oncol; 2018 Jan 02; 29(1):e12. PubMed ID: 29185270
    [Abstract] [Full Text] [Related]

  • 12. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
    Stoeckle E, Bourdarias L, Guyon F, Croce S, Brouste V, Thomas L, Floquet A.
    Ann Surg Oncol; 2014 Feb 02; 21(2):629-36. PubMed ID: 24052318
    [Abstract] [Full Text] [Related]

  • 13. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.
    Int J Gynecol Cancer; 2017 May 02; 27(4):708-713. PubMed ID: 28441251
    [Abstract] [Full Text] [Related]

  • 14. The optimal time for surgery in women with serous ovarian cancer.
    Stewart JM, Tone AA, Jiang H, Bernardini MQ, Ferguson S, Laframboise S, Murphy KJ, Rosen B, May T.
    Can J Surg; 2016 Aug 02; 59(4):223-32. PubMed ID: 27240134
    [Abstract] [Full Text] [Related]

  • 15. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.
    Gynecol Oncol; 2016 May 02; 141(2):260-263. PubMed ID: 26968641
    [Abstract] [Full Text] [Related]

  • 16. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis.
    Kim SR, Parbhakar A, Li X, Bernardini MQ, Hogen L, May T.
    Int J Gynecol Cancer; 2024 Jun 03; 34(6):879-885. PubMed ID: 38548312
    [Abstract] [Full Text] [Related]

  • 17. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A, Manning-Geist B, Bregar AJ, Diver EJ, Goodman A, Del Carmen MG, Schorge JO, Rauh-Hain JA.
    Gynecol Oncol; 2017 Nov 03; 147(2):250-256. PubMed ID: 28822556
    [Abstract] [Full Text] [Related]

  • 18. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
    Seagle BL, Graves S, Strohl AE, Shahabi S.
    Int J Gynecol Cancer; 2017 Oct 03; 27(8):1610-1618. PubMed ID: 28763362
    [Abstract] [Full Text] [Related]

  • 19. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.
    Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    BMC Cancer; 2020 Mar 04; 20(1):185. PubMed ID: 32131779
    [Abstract] [Full Text] [Related]

  • 20. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    Am J Obstet Gynecol; 2017 Sep 04; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.